Intratumoral delivery of β-lapachone via polymer implants for prostate cancer therapy

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 131-139

  Dong, Ying ^a   Chin, Shook Fong ^a   Blanco, Elvin ^a   Bey, Erik A ^a   Kabbani, Wareef ^b   Xie, Xian Jin ^a,c   Bornmann, William G ^d   Boothman, David A ^a   Gao, Jinming ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; BETA LAPACHONE; POLYGLACTIN; POLYMER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL KILLING; CELL SURVIVAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG IMPLANT; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; SOLID STATE; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG IMPLANTS; HUMANS; MALE; MICE; MICE, NUDE; NAPHTHOQUINONES; POLYMERS; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58849156956     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1691     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Huang WC, Lee CL, Eastham JA. Locally ablative therapies for primary radiation failures: a review and critical assessment of the efficacy. Curr Urol Rep 2007;8:217-23
3. Bracarda S, de Cobelli O, Greco C, et al. Cancer of the prostate. Crit Rev Oncol Hematol 2005;56:379-96.
4. Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. β-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp Cell Res 2001;267:95-106.
5. Ough M, Lewis A, Bey EA, et al. Efficacy of β-lapa-chone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther 2005;4:95-102.
6. Bey EA, Bentle MS, Reinicke KE, et al. An NQO1 - and PARP-1-mediated cell death pathway induced in nonsmall-cell lung cancer cells by β lapachone. Proc Natl Acad Sci U S A 2007;104:11832 - 7
7. Bentle MS, Reinicke KE, Bey EA. Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 2006;281:33684-96.
8. Pink JJ, Planchon SM,Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of b-lapachone cytotoxicity. J Biol Chem 2000;275:5416-24.
9. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in -βlapachone-mediated cell death. J Biol Chem 2001; 276:19150-9.
10. Reinicke KE, Bey EA, Bentle MS, et al. Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P) H:quinone oxidore-ductase 1 levels. Clin Cancer Res 2005;11:3055-64.
11. Nasongkla N, Wiedmann AF, Bruening A, et al. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharm Res 2003;20:1626-33.
12. Tewari A, Raman JD, Chang P, Rao S, Divine G, Menon M. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 2006; 68:1268-74.
13. LaVan DA, McGuireT, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;21:1184-91.
14. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41:403-19.
15. Ewend MG, Elbabaa S, Carey LA. Current treatment paradigms for the management of patients with brain metastases. Neurosurgery 2005;57:S66-77; discussion S1 -4.
16. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R, A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 2005;72:241 -4.
17. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: longterm follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148:269-75: discussion 75.
18. He YC, Chen JW, Cao J, Pan DY, Qiao JG. Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats. World J Gastroenterol 2003;9:1795-8.
19. Qian F, Stowe N, Liu EH, Saidel GM, Gao J. Quantification of in vivo doxorubicin transport from PLGA millirods in thermoablated rat livers. J Control Release 2003;91:157-66.
20. Qian F, Szymanski A, Gao J. Fabrication and characterization of controlled release poly(D L-lactide-co-gly-colide) millirods. J Biomed Mater Res 2001;55:512 - 22.
21. Szymanski-Exner A, Gallacher A, Stowe NT, Weinberg B, Haaga JR, Gao J. Local carboplatin delivery and tissue distribution in livers after radiofrequency ablation. J Biomed Mater Res A 2003;67:510-6.
22. Weinberg BD, Ai H, Blanco E, Anderson JM, Gao J. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A 2007;81:161 - 70.
23. Wang F, Blanco E, Ai H, Boothman DA, Gao J. Modulating β-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci 2006;95:2309-19
24. Planchon SM, Wuerzberger S, Frydman B, et al. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995;55:3706-11.
25. Steiner M, Hillenbrand M, Borkowsi M, Seiter H, Schuff-Werner P. 609 C -» T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett 1999;135:67-71.
26. Radjendirane V, Joseph P, Lee YH, et al. Disruption of the DTdiaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998;273:7382-9.
27. Heysek RV. Modern brachytherapy for treatment of prostate cancer. Cancer Control 2007;14:238-43.
28. Beer TM, El-Geneidi M, Eilers KM. Docetaxel (taxo-tere) in the treatment of prostate cancer. Expert Rev AnticancerTher 2003;3;261 -8.
29. Small EJ. Docetaxel in prostate cancer. Anticancer Drugs 2001;12 Suppl 1:S17-20.
30. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171 -87.
31. Downing SR, Jackson P, Russell PJ. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. A review of the evidence. Urol Oncol 2001;6:103-10.
32. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 2003;10:1924-33.
33. Prevarskaya N, Skryma R, Shuba Y. Ca2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun 2004;322:1326-35.
34. Coffey RN, Watson RW, Fitzpatrick JM. Signaling for the caspases: their role in prostate cell apoptosis. J Urol 2001;165:5-14.
35. Perry J, Chambers A, Spithoff K, Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 2007;14:189-94.
36. Ortiz R, Au JL, Lu Z, Gan Y, Wientjes MG. Biodegradable intraprostatic doxorubicin implants. AAPS J 2007;9:E241 -50.
37. Weinberg BD, Blanco E, Lempka SF, Anderson JM, Exner AA, Gao J. Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. J Biomed Mater Res A 2007;81:205-13.
38. Miyamoto S, Huang TT, Wuerzberger-Davis S, et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N YAcad Sci 2000;922:274-92.